arrow
Y

Yusuke Miyazaki

University of Occupational and Environmental Health
H指数:19
被引数:1,516

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Effectiveness of biological disease-modifying antirheumatic drugs in progressive pulmonary fibrosis associated with rheumatoid arthritis

类风湿关节炎相关进行性肺纤维化中生物制剂改善病情抗风湿药的有效性

2026-08-200
PRE
Effectiveness and safety of sarilumab in polymyalgia rheumatica: A retrospective study of the FIRST registry

沙利鲁单抗在风湿性多肌痛中的有效性与安全性:FIRST登记研究的回顾性研究

2026-01-010
PRE
Association of exercise-induced pulmonary hypertension with nailfold capillary density in systemic sclerosis: a single-center retrospective observational study

运动诱发性肺动脉高压与系统性硬化症中甲襞毛细血管密度的关联:一项单中心回顾性观察性研究

2025-08-290
OA
Effective Second-Line b/tsDMARDs for Patients with Rheumatoid Arthritis Unresponsive to First-Line b/tsDMARDs from the FIRST Registry

FIRST注册研究中对对一线b/tsDMARDs无应答的类风湿关节炎患者有效的二线b/tsDMARDs

2025-03-011
OA
Switching to biological DMARDs versus cycling among JAK inhibitors in patients with rheumatoid arthritis and with inadequate response to JAK inhibitors: from FIRST registry

将生物DMARDs与JAK抑制剂序贯疗法用于对JAK抑制剂应答不足的类风湿关节炎患者:来自FIRST注册研究

2025-01-211
OA
SAFETY AND EFFICACY OF ANIFROLUMAB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) WITH MINOR FLARES AFTER ACHIEVING THE LUPUS LOW DISEASE ACTIVITY STATE (LLDAS) IN REAL-WORLD CLINICAL PRACTICE:LOOPS REGISTRY

系统性红斑狼疮(SLE)患者达到狼疮低疾病活动状态(LLDAS)后,在真实世界临床实践中,出现轻微复发时anifrolumab的安全性与有效性:LOOPS注册研究

2024-06-010
PRE
PERIPHERAL BLOOD IMMUNOPHENOTYPE OF PATIENTS WITH SLE IN MAINTENANCE PHASE WHO WERE ABLE TO DISCONTINUE GLUCOCORTICOIDS AFTER INTERVENTION WITH BELIMUMAB: LOOPS REGISTRY, FLOW STUDY

接受贝利木单抗干预后能够停用糖皮质激素的SLE维持期患者的 peripheral blood immunophenotype:LOOPS登记研究,FLOW研究

2024-06-010
PRE